Volume 16, Number 5—May 2010
Research
Effects of Pneumococcal Conjugate Vaccine 2 Years after Its Introduction, the Netherlands
Figure 1
![Figure 1. Incidence of invasive pneumococcal disease in children <2 years of age in the birth group born after April 1, 2006 (age eligible for 7-valent pneumococcal conjugate vaccine [PCV-7]) and children born before April 1, 2006 (age noneligible for PCV-7), in the postimplementation period compared with age-matched children in the preimplementation period, the Netherlands. Incidence per 100,000 children <2 years of age per year; Pre, preimplementation period (June 2004–June 2006); post, postimplementation period (June 2006–June 2008). Incidence of invasive pneumococcal disease in children <2 years of age in the birth group born after April 1, 2006 (age eligible for 7-valent pneumococcal conjugate vaccine [PCV-7]) and children born before April 1, 2006 (age noneligible for PCV-7), in the postimplementation period compared with age-matched children in the preimplementation period, the Netherlands. Incidence per 100,000 children <2 years of age per year; Pre, preimplementation period (June 2004–June 2006); post, postimplem](/eid/images/09-1223-F1.jpg)
Figure 1. Incidence of invasive pneumococcal disease in children <2 years of age in the birth group born after April 1, 2006 (age eligible for 7-valent pneumococcal conjugate vaccine [PCV-7]) and children born before April 1, 2006 (age noneligible for PCV-7), in the postimplementation period compared with age-matched children in the preimplementation period, the Netherlands. Incidence per 100,000 children <2 years of age per year; Pre, preimplementation period (June 2004–June 2006); post, postimplementation period (June 2006–June 2008).